A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
Study Identifier:
ACH471-201
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Danicopan
Date
Aug 2017 - Dec 2018
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 16 - 65 Years
Requirements Information
Sex
Female & Male
Age
16 - 65 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Danicopan
Date
Aug 2017 - Dec 2018
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 16 - 65 Years years
Requirements Information
Protocol Summary
The primary objective of this study was to determine whether ACH-0144471 (also known as danicopan and ALXN2040) increases blood C3 complement protein (C3) levels in participants with low C3 levels due to either C3G or IC-MPGN.
Trial Locations
Location
Status
Location
Clinical Trial Site
Melbourne, Australia
Status
N/A
Location
Clinical Trial Site
Antwerpen, Belgium
Status
N/A
Location
Clinical Trial Site
Leiden, Netherlands
Status
N/A